Ceapro Inc.

TSX VENTURE : CZO


Ceapro Inc.

April 19, 2011 09:00 ET

Ceapro's Announces Additional Key Patents Granted in Europe, Japan and United States of America

EDMONTON, ALBERTA--(Marketwire - April 19, 2011) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the Company") is pleased to announce that patent offices in Europe, Japan and USA have issued the following patents to protect Ceapro's inventions:

  • One of our core products, Avenanthramides: the office of the USA patents has issued patent US # 7,887,823 "Oat Extracts: Refining, Compositions and Methods of Use" to protect Ceapro's invention related to a manufacturing process for avenanthramides, to their composition and for their application in cosmetics, medical treatment and veterinary.

  • Japan: "Improved Extraction and Purification Method for Cereal Beta glucan"

  • Europe: CeaproveĀ® "Diagnostic Composition For Diabetes Type-2 And Impaired Glucose Tolerance, And Methods Of Use".

"The granting of these key patents is a culmination of many years of research and represent a very important milestone for the further development of our active ingredients in the nutraceutical and or pharmaceutical fields where patent protection is so important to secure partnerships, ensure successful product commercialization and future sales. said Gilles Gagnon, Acting President & CEO.

The complete audited annual report and financial statements are available for review on SEDAR at http://sedar.com/Ceapro and on the Company's website at www.ceapro.com .

About Ceapro Inc.

Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business activities relate to the development and commercialization of active ingredients for personal care and cosmetic industries using proprietary technology and natural, renewable resources. To learn more about Ceapro, visit www.ceapro.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information